Concord Wealth Partners Exelixis, Inc. Transaction History

Concord Wealth Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$17.44 - $23.16 $8,092 - $10,746	-464 Closed	0 $0
Q1 2022 Apr 20, 2022	BUY	$17.03 - $22.67 $1,498 - $1,994	88 Added 23.4%	464 $11,000
Q4 2021 Jan 21, 2022	BUY	$15.84 - $21.88 $2,027 - $2,800	128 Added 51.61%	376 $7,000
Q3 2021 Nov 09, 2021	BUY	$16.3 - $21.14 $2,917 - $3,784	179 Added 259.42%	248 $5,000
Q2 2021 Jul 29, 2021	BUY	$17.95 - $25.56 $1,238 - $1,763	69 New	69 $1,000

565

251M

1.45M

1.13M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.